2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses how to determine patients with high-risk chronic lymphocytic leukemia (CLL).
Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses how to determine patients with high-risk chronic lymphocytic leukemia (CLL).
The patients need to have a high-risk cytogenetic feature that predicts shorter survival from CLL and a shorter time to needing treatment, explains Rogers. An example of a cytogenetic feature is 17p deletion.
According to Rogers, patients with lower-risk disease can go decades without needing treatment. However, a patient with high-risk CLL will need treatment in 1 to 2 years. A potential therapy for high-risk patients is the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) since it demonstrated an objective response rate (ORR) of 78% in the phase III GENUINE study. This trial also demonstrated that ublituximab in combination with ibrutinib yields superior ORR to ibrutinib alone, which was 45% in high-risk CLL.